On April 12, 2021 Jubilant Therapeutics Inc. , a biopharmaceutical company developing oral, small molecule modulators to meet unmet medical needs in oncology and autoimmune diseases, reported preclinical data from two programs investigating the company’s PRMT5 inhibitor and PD-L1 inhibitor as anticancer agents will be unveiled today in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, which will be held virtually from Nov. takes place until April 15 , 2021 (Press release, Jubilant Therapeutics, APR 12, 2021, View Source;pgid=1475&pressid=449 [SID1234577941]) .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce these important data from our PRMT5 and PD-L1 programs that demonstrate efficacy and tolerability in preclinical models," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics Inc. "Our oral PRMT5 inhibitor has good plasma and sustained brain exposure resulting in potent target inhibition, tumor growth delay, and a survival benefit in both xenografts and orthotopic brain models . Our shorter half-life oral anti-PDL1 immunotherapeutics are an attractive alternative to current intravenous antibody therapies, especially in the maintenance phase, with the potential to limit immune-mediated toxicities and side effects through innovative dosage approaches while maintaining class-based broad anti-tumor efficacy. We look forward to continuing our work on these programs as we see great potential for treating various types of cancer. "

A link to the e-posters listed below is available on the AACR (Free AACR Whitepaper) website.

Title: Novel Small Molecular Weight PRMT5 Inhibitors for the Treatment of Cancer
Poster Number: 1128
Date and Time: April 10 , 2021 at 8:30 a.m. Eastern Daylight Time (EDT)
Session Title: Epigenetic Targets
Speaker: Dhanalakshmi Sivanandhan, et al.

Title: Novel Small Molecular Weight Inhibitors of PD-L1 / PD-1 Interaction
Poster Number: 1630
Date and Time: April 10 , 2021 at 8:30 a.m. Eastern Daylight Time (EDT)
Session Title: Immune Checkpoints
Speaker (r ): Dhanalakshmi Sivanandhan, et al.

The overexpression of PRMT5, which has been demonstrated in various types of cancer such as lymphatic cancer, lung cancer, breast cancer, glioblastoma, gastric cancer, etc., is considered to be an important factor in tumorigenicity due to its repressive function on the expression of tumor suppressor genes. The most important highlights from an evaluation that examined the inhibition of tumor growth by the PRMT5 inhibitor JBI-778 in various cancer cell lines as well as in glioblastoma are as follows:

JBI-778 is a potent PRMT5 inhibitor that acts selectively against other PRMTs;
JBI-778 is a potent PRMT5 inhibitor that acts selectively against other PRMTs;
This orally administered small molecule demonstrated anti-tumor activity in a mantle cell lymphoma model with an ED50 of <10 mg / kg and complete inhibition of tumor growth (97%) at a dose of 50 mg / kg; and
JBI-778 demonstrated sustained exposure of the brain and significant inhibition of tumor growth in an orthotopic glioblastoma model, resulting in a significant survival benefit.
JBI-778 is currently being investigated for the treatment of a variety of cancers and IND-approved studies have begun.

PD-L1 expression is an immune evasion mechanism that is exploited by many cancers, including melanoma, non-small cell lung cancer, and breast cancer, that enables cancer to progress and metastasize. Key findings from the PD-L1 / PD-1 Study, which examined the ability of JBI-1527 to inhibit PD-L1 and restore T cell proliferation and function, included:

JBI- 1527 is a potent, selective inhibitor of PD-L1, which induces the dimerization of the protein and thereby reduces the PD-L1-induced suppression of T-cell activation;
The inhibitor shows a similar modulation of cytokines as pembrolizumab in the BioMAP assay and competes with the anti-PD-L1 blocking antibody, suggesting a similar binding site on PD-L1; and
In syngeneic CT-26 and MC38-hPD-L1 models, the small molecule showed a strong inhibition of tumor growth, comparable to anti-PD-L1 mAb / atezolizumab, and was well tolerated.
Studies to further evaluate JBI-1527 and other substances are ongoing.